ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(20), P. 19550 - 19580
Published: Oct. 11, 2023
In
late
2020,
the
U.S.
Food
and
Drug
Administration
(FDA)
approved
a
lipid-based
mRNA
vaccine
for
prevention
of
COVID-19,
which
has
pushed
this
field
to
be
more
closely
studied
motivated
researchers
delve
deeper
into
therapeutics.
To
date,
research
on
cancer
vaccines
been
developed
rapidly,
substantial
hopeful
therapeutic
results
have
achieved
against
various
solid
tumors
in
clinical
trials.
review,
we
first
introduce
three
main
components
vaccines,
including
antigens,
adjuvants,
delivery
vectors.
Engineering
these
can
optimize
effects
vaccines.
For
instance,
appropriate
modification
structure
alleviate
poor
stability
innate
immunogenicity
mRNA,
use
vectors
address
issues
low
efficiency
vivo.
Second,
emphatically
discuss
some
strategies
further
improve
efficacy
namely
modulating
immunosuppressive
tumor
environment,
optimizing
administration
routes,
achieving
targeting
intended
tissues
or
organs,
employing
combination
therapy.
These
strengthen
inhibitory
ability
increase
possibility
elimination.
Finally,
point
out
challenges
practice
offer
our
perspectives
future
developments
rapidly
evolving
field.
It
is
anticipated
that
will
therapy
near
future.
Nanomaterials,
Journal Year:
2025,
Volume and Issue:
15(2), P. 126 - 126
Published: Jan. 16, 2025
Chitosan,
a
multifaceted
amino
polysaccharide
biopolymer
derived
from
chitin,
has
extensive
antibacterial
efficacy
against
diverse
pathogenic
microorganisms,
including
both
Gram-negative
and
Gram-positive
bacteria,
in
addition
to
fungi.
Over
the
course
of
last
several
decades,
chitosan
nanoparticles
(NPs),
which
are
polymeric
bio-based,
have
garnered
great
deal
interest
as
efficient
agents.
This
is
mostly
due
fact
that
they
used
wide
variety
applications,
medical
treatments,
food,
chemicals,
agricultural
products.
Within
context
mechanism
NPs,
we
present
review
provides
an
overview
synthesis
methods,
novel
procedures,
compiles
applications
been
developed
field
biomedicine.
These
include
wound
healing,
drug
delivery,
dental
treatment,
water
purification,
agriculture,
food
preservation.
In
this,
focus
on
mechanisms
action
factors
determine
activity
its
derivatives.
conjunction
with
this
line
inquiry,
researchers
strongly
urged
concentrate
their
efforts
developing
ground-breaking
NPs.
Acta Pharmaceutica Sinica B,
Journal Year:
2023,
Volume and Issue:
13(5), P. 2176 - 2187
Published: Feb. 21, 2023
Intelligent
responsive
drug
delivery
system
opens
up
new
avenues
for
realizing
safer
and
more
effective
combination
immunotherapy.
Herein,
a
kind
of
tumor
cascade-targeted
liposome
(NLG919@Lip-pep1)
is
developed
by
conjugating
polypeptide
inhibitor
PD-1
signal
pathway
(AUNP-12),
which
also
targeted
peptide
that
conjugated
with
carrier
through
matrix
metalloproteinase-2
(MMP-2)
cleavable
(GPLGVRGD).
This
prepared
mature
preparation
process,
indoleamine-2,3-dioxygenase
(IDO)
NLG919
was
encapsulated
into
it.
Moreover,
mediated
the
enhanced
permeability
retention
effect
(EPR
effect)
AUNP-12,
NLG919@Lip-pep1
first
targets
cells
highly
express
PD-L1
in
tissues.
At
same
time,
over-expressed
MMP-2
site
triggers
dissociation
thus
precise
block
pathway,
restoring
activity
T
cells.
The
exposure
secondary
targeting
module
II
VRGDC-NLG919@Lip
targeting,
further
relieved
immunosuppressive
microenvironment.
Overall,
this
study
offers
potentially
appealing
paradigm
high
efficiency,
low
toxicity,
simple
intelligent
breast
cancer,
can
effectively
rescue
activate
body's
anti-tumor
immune
response
furthermore
achieve
treatment
metastatic
cancer.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(20), P. 19550 - 19580
Published: Oct. 11, 2023
In
late
2020,
the
U.S.
Food
and
Drug
Administration
(FDA)
approved
a
lipid-based
mRNA
vaccine
for
prevention
of
COVID-19,
which
has
pushed
this
field
to
be
more
closely
studied
motivated
researchers
delve
deeper
into
therapeutics.
To
date,
research
on
cancer
vaccines
been
developed
rapidly,
substantial
hopeful
therapeutic
results
have
achieved
against
various
solid
tumors
in
clinical
trials.
review,
we
first
introduce
three
main
components
vaccines,
including
antigens,
adjuvants,
delivery
vectors.
Engineering
these
can
optimize
effects
vaccines.
For
instance,
appropriate
modification
structure
alleviate
poor
stability
innate
immunogenicity
mRNA,
use
vectors
address
issues
low
efficiency
vivo.
Second,
emphatically
discuss
some
strategies
further
improve
efficacy
namely
modulating
immunosuppressive
tumor
environment,
optimizing
administration
routes,
achieving
targeting
intended
tissues
or
organs,
employing
combination
therapy.
These
strengthen
inhibitory
ability
increase
possibility
elimination.
Finally,
point
out
challenges
practice
offer
our
perspectives
future
developments
rapidly
evolving
field.
It
is
anticipated
that
will
therapy
near
future.
